Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more

Kontani,Keiichi; Hashimoto,Shin-Ichiro; Murazawa,Chisa; Norimura,Shoko; Tanaka,Hiroaki; Ohtani,Masahiro; Fujiwara-Honjo,Naomi; Date,Manabu; Houchi,Hitoshi; Yokomise,Hiroyasu

doi:10.3892/mco.2012.49

Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more

Authors:
- Keiichi Kontani
- Shin-Ichiro Hashimoto
- Chisa Murazawa
- Shoko Norimura
- Hiroaki Tanaka
- Masahiro Ohtani
- Naomi Fujiwara-Honjo
- Manabu Date
- Hitoshi Houchi
- Hiroyasu Yokomise
View Affiliations

Affiliations: Department of Respiratory, Breast and Endocrine Surgery, Kagawa University Faculty of Medicine, Kagawa University Hospital, Kita-gun, Kagawa 761-0793, Japan, Department of Surgery, Takamatsu Red Cross Hospital, Takamatsu, Kagawa 760‑0017, Japan, Department of Pharmacy, Kagawa University Hospital, Kita-gun, Kagawa 761-0793, Japan, Kagawa Health Service Association, Health Care Center, Takamatsu, Kagawa 761-8071, Japan, Department of Radiology, Osaka Neurosurgery Hospital, Takamatsu 761-8083, Japan, Department of Surgery, Date Hospital, Takamatsu, Kagawa 760-0076, Japan
Published online on: December 10, 2012 https://doi.org/10.3892/mco.2012.49
Pages: 225-230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of treatment for metastatic breast cancer (MBC) is to control the disease or disease‑related symptoms. Prolonged survival has also often been achieved by chemotherapeutic regimens in this setting. Long‑term administration of one therapeutic regimen is essential for prolonging survival as well as for maintaining quality of life in these patients. In this study, we focused on time to treatment failure (TTF) as a parameter that predicts patient survival and we retrospectively compared clinical outcomes of patients with MBC who showed TTF of ≥12 months (26 patients) and <12 months (29 patients). The proportion of hormone receptor‑positive tumors and the number of prior chemotherapy regimens for MBC were significantly higher and tumor grade was lower in patients with TTF ≥12 months compared to those with TTF <12 months. With regard to clinical outcomes, the objective response rate (ORR) in patients with TTF ≥12 months was significantly higher and median time to progression (TTP) and overall survival (OS) were longer compared to those with TTF <12 months. Of note, the proportion of patients who received metronomic regimens was significantly higher in patients with TTF ≥12 months compared to those with TTF <12 months (80.8 vs. 24.1%, P=0.00003). To assess the clinical benefit of metronomic regimens, the efficacy in patients receiving metronomic and those receiving non‑metronomic regimens was compared. Although there was no difference in ORR between the two groups, median TTP and OS were significantly longer in the metronomic compared to the non‑metronomic group (TTP: 30 vs. 4 months, P=0.0017; OS: 68 vs. 28 months, P=0.0005). The results suggested that metronomic chemotherapy is useful for palliative care and also improved clinical outcomes as a regimen for which long‑term administration may be expected.

View Figures

View References

1	Smith I and Chua S: Medical treatment of early breast cancer. I: adjuvant treatment. BMJ. 332:34–37. 2006. View Article : Google Scholar : PubMed/NCBI
2	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
3	Bria E, Nistico C, Cuppone F, et al: Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 106:2337–2344. 2006. View Article : Google Scholar : PubMed/NCBI
4	Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 8:1073–1079. 2002.PubMed/NCBI
5	Bontenbal M, Andersson M, Wildiers J, et al: Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer. 77:2257–2263. 1998. View Article : Google Scholar : PubMed/NCBI
6	Jassem J, Pieńkowski T, Płuzańska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 19:1707–1715. 2001.
7	Perez DJ, Harvey VJ, Robinson BA, et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol. 9:2148–2152. 1991.PubMed/NCBI
8	Bonneterre J, Dieras V, Tubiana-Hulin M, et al: Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 91:1466–1471. 2004.PubMed/NCBI
9	Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003. View Article : Google Scholar : PubMed/NCBI
10	Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for meta-static breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 18:724–733. 2000.
11	Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 17:2341–2354. 1999.PubMed/NCBI
12	Rha SY, Moon YH, Jeung HC, et al: Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 90:215–221. 2005. View Article : Google Scholar : PubMed/NCBI
13	Spielmann M, Llombart-Cussac A, Kalla S, et al: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 60:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
14	Zelek L, Barthier S, Riofrio M, et al: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 92:2267–2272. 2001. View Article : Google Scholar
15	Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB and Ambrosini G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol. 12:2094–2101. 1994.PubMed/NCBI
16	Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 92:1759–1768. 2001. View Article : Google Scholar : PubMed/NCBI
17	Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 17:485–493. 1999.PubMed/NCBI
18	Jassem J, Carroll C, Ward SE, Simpson E and Hind D: The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer. 45:2749–2758. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pivot XB, Li RK, Thomas ES, et al: Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer. 45:2940–2946. 2009. View Article : Google Scholar
20	Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T and Hatake K: Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine. Breast Cancer. 16:126–131. 2009. View Article : Google Scholar : PubMed/NCBI
21	Savio G, Laudani A, Leonardi V, Pepe A, Scianna C, Gebbia V and Agostara B: Treatment of metastatic breast cancer with vinorelbine and docetaxel. Am J Clin Oncol. 29:276–280. 2006. View Article : Google Scholar : PubMed/NCBI
22	Vici P, Di Lauro L, Sergi D, et al: A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology. 75:175–181. 2008. View Article : Google Scholar : PubMed/NCBI
23	Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with meta-static breast cancer and prior anthracycline treatment. J Clin Oncol. 26:3950–3957. 2008. View Article : Google Scholar : PubMed/NCBI
24	Chan S, Romieu G, Huober J, et al: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 27:1753–1760. 2009. View Article : Google Scholar : PubMed/NCBI
25	O’Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 20:2812–2823. 2002.PubMed/NCBI
26	Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT and Ottevanger PB: Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol. 12:1053–1061. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI
28	Colleoni M, Rocca A, Sandri MT, et al: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 13:73–80. 2002. View Article : Google Scholar : PubMed/NCBI
29	Colleoni M, Orlando L, Sanna G, et al: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 17:232–238. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wong NS, Buckman RA, Clemons M, et al: Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol. 28:723–730. 2010.
31	Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 21:968–975. 2003. View Article : Google Scholar : PubMed/NCBI
32	Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
33	Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 40:536–542. 2004. View Article : Google Scholar : PubMed/NCBI